Home
News
Your Voice
Links
Jobs
Sitemap
Contact
YOU ARE HERE: >
Kernow Clinical Commissioning Group
>
Formulary Information
>
Information Page
Home
Drugs
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Chapters
KCC Referral
Management System
Shared Care
Guidelines
Care Home
Resources
Local Resource
Packs
Chronic Pain
in Cornwall
Diabetes Resources
Respiratory Resources
Flu Resource Pack
Patient Group Direction (PGD)
Palliative Care Resources
Search
Search Drugs
Search BNF Categories
Notes
Click to View ALL BNF
Ch1 Gastro
Ch2 Cardio
Ch3 Respiratory
Ch4 CNS
Ch5 Infections
Ch6 Endocrine
Ch7 Obs & Gynae
Ch8 Malignant Disease
Ch9 Nutrition & Blood
Ch10 Muscuskeletal
Ch11 Eye
Ch12 Ear, Nose, Oropharynx
Ch13 Skin
Ch14 Immunological
Ch15 Anaesthesia
Ch19 Other Dugs
ch20 Dressings
ch21 Appliances
ch22 Incontinence appliances
ch23 Stoma appliances
>>
1. Cytotoxic Drugs
2. Drugs Affecting The Immune Response
3. Sex Hormones & Antag In Malig Disease
>>
0. Drugs for Cytotoxic-Induced side-effects
0. Alkylating Drugs
0. Anthracyclines & Cytotoxic Antibiotics
0. Antimetabolites
0. Vinca alkaloids and etoposide
0. Other Antineoplastic Drugs
(Click to View Drug List)
Cost
Cost
Packs
Packs
Items
Items
Loading…
Summary:
Notes
Notes
NICE Guidance (11)
NICE Guidance (11)
Other Links (4)
Other Links (4)
Important Local Documents (0)
Important Local Documents (0)
No notes available
NICE Guidance (BNF Sub Paragraph Level) for - Antimetabolites
10/04/2013
TA100 Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)
10/04/2013
TA61 Colorectal cancer - capecitabine and tegafur uracil (TA61)
10/04/2013
TA191 Gastric cancer (advanced) - capecitabine (TA191)
10/04/2013
TA116 Breast cancer - gemcitabine (TA116)
10/04/2013
TA25 Pancreatic cancer - gemcitabine (TA25)
10/04/2013
TA135 Mesothelioma - pemetrexed disodium (TA135)
10/04/2013
TA181 Lung cancer (non-small-cell, first line treatment) - pemetrexed (TA181)
10/04/2013
TA190 Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)
10/04/2013
TA218 Myelodysplastic syndromes - azacitidine (TA218)
NICE Guidance (BNF Section Level) for - Cytotoxic Drugs
23/11/2021
TA747 Nintedanib for treating progressive fibrosing interstitial lung diseases
23/11/2021
TA746 Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer
Other links (BNF Section Level) for - Cytotoxic Drugs
26/10/2020
DSU 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity
26/10/2020
DSU Niraparib (Zejula): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
12/07/2021
DSU - Atezolizumab (Tecentriq) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)
12/07/2021
DSU - CDK4/6 inhibitors (abemaciclib, palbociclib, ribociclib): reports of interstitial lung disease and pneumonitis, including severe cases
No files available
Loading…
Cornwall Joint Formulary Recommended Choices
(...Top)
Displaying 4 Drugs
Key:
First Line Drugs
Second Line Drugs
Specialist advised
Specialist Initiated Drugs
Hospital Only Drugs
Discouraged
No comment available
Name
Tariff
BNF Sub Paragraph
Fluorouracil Cream (Efudix)
5 % cream (40g tube) Pack of 40
£32.90
Antimetabolites
Antimetabolites
Antimetabolites
For actinic keratosis for areas up to 500cm2 Additional information may be found on Cornwall RMS
Methotrexate
2.5 mg tab Pack of 100
£4.80
Antimetabolites
Used as a weekly dose only
Mercaptopurine
50 mg tablets Pack of 25
£8.39
Antimetabolites
Mercaptopurine Solution
100 mg / 5 mL Suspension (Special) Pack of 1
-
Antimetabolites
© Kernow Clinical Commissioning Group 2024 - All Rights Reserved
The Sedgemoor Centre, Priory Road, St Austell, Cornwall, PL25 5AS